Investor's Business Daily on MSN21h
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
Hims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide.
Morgan Stanley says Hims branded tirzepatide margins likely well below compounds
After Hims & Hers (HIMS) announced yesterday that the company is broadening its weight loss offering to include Lilly’s (LLY) branded ...
Physician's Weekly11h
Zepbound Now Available Through Hims AND Hers
The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.
Citi sees high price of Tirzepatide on Hims & Hers being ‘prohibitive’
Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...
Futurism on MSN4d
Hims Is Begging Customers to Lobby the FDA to Keep Its Ozempic Knockoffs Legal
As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.
‘Hold the Phone,’ Says Morgan Stanley on Hims & Hers Health Stock (HIMS)
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs
Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...
Investor's Business Daily on MSN21h
Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch
Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.